What is Larazotide?
An oral 8-amino-acid peptide that tightens intestinal junctions by blocking zonulin signaling; studied in celiac disease through phase 3.
Larazotide in the library · Healing & Repair Peptides · Human Trials · What are peptides?
10 registered trials · 5 indexed papers · 2398 human / 356 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Larazotide acetate is described as an oral octapeptide designed to reduce gut permeability by countering zonulin, a protein that loosens tight junctions.
Mechanism (as described)
- It acts locally in the gut to limit tight-junction opening triggered by gluten and other stimuli (Troisi et al., 2021).
Status
Investigational; not approved.
Registered human trials (10)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| AT1001 for the Treatment of Long COVID | Phase 2 | completed | 2023 | 107 |
| AT1001 for the Treatment of COVID-19 Related MIS-C | Phase 2 | terminated | 2021 | 12 |
| Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms | Phase 3 | terminated | 2019 | 307 |
| A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease | Phase 2 | completed | 2011 | 342 |
| Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease | Phase 2 | completed | 2009 | 42 |
| Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease | Phase 2 | completed | 2008 | 105 |
| Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease | Phase 2 | completed | 2007 | 171 |
| Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects | Phase 2 | completed | 2006 | 80 |
| Safety of Larazotide Acetate in Healthy Volunteers | Phase 1 | completed | 2006 | 24 |
| Safety Study of Larazotide Acetate to Treat Celiac Disease. | Phase 1 | completed | 2005 | 21 |
Peer-reviewed studies (5)
More cited research
- Tight junction regulation in celiac disease: role of larazotide acetate (2022, human observational)
- [Larazotide as an option in case of failure of a gluten-free diet] (2016, human observational)
- Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model (2026, animal)
- Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment (2025, animal)
- Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats (2024, animal)
- Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats (2021, animal)
Conditions researched
Related compounds
- GIP (Gastric Inhibitory Polypeptide)
- Parathyroid Hormone (PTH 1-84)
- Teduglutide (GLP-2 analog)
- ACTH (Corticotropin)
- ANP (Atrial Natriuretic Peptide)
- Adrenomedullin
- Alpha-MSH
- Angiotensin II
- BNP (Nesiritide)
- Bestim
FAQ
What is Larazotide?
An oral 8-amino-acid peptide that tightens intestinal junctions by blocking zonulin signaling; studied in celiac disease through phase 3.
How many registered human trials study Larazotide?
The PeptideWhiz trial index lists 10 registered trials for Larazotide, the most recent from 2023.
How much published research exists on Larazotide?
The PeptideWhiz paper index links 5 PubMed papers to Larazotide; by study type, 2398 human and 356 animal studies.
Which conditions is Larazotide researched for?
Celiac disease and gluten sensitivity, Immune system (general).
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).